Literature DB >> 11157488

Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus.

H Nagata1, A Konno, N Kimura, Y Zhang, M Kimura, A Demachi, T Sekine, K Yamamoto, N Shimizu.   

Abstract

Studies on nasal T/natural killer (NK)-cell lymphoma have been hampered by its tendency to cause necrosis. Thus, the establishment of cell lines of this neoplasm would seem to be valuable. This study attempted to establish cell lines from primary lesions of this tumor, and successfully obtained 2 novel Epstein-Barr virus (EBV)-positive cell lines, SNK-6 and SNT-8, by means of high-dose recombinant interleukin 2. Flow cytometry showed that SNK-6 had an NK-cell phenotype, CD3- CD4- CD8- CD19- CD56+ T-cell receptor (TCR) alpha/beta- TCR gamma/delta-, whereas SNT-8 was CD3+ CD4- CD8- CD19- CD56+ TCR alpha/beta- TCR gamma/delta+. These were consistent with immunophenotypes of their original tumors, and the cell lines had monoclonal EBV clones identical to ones in their original tumors. Thus, the cell lines developed from cells forming the primary lesions. Genotypic analysis showed that SNK-6 had unrearranged TCR and immunoglobulin heavy-chain genes, supporting the conclusion that SNK-6 was of NK-cell lineage. On the other hand, SNT-8 had rearranged TCR beta-, gamma-, and delta-chain genes, and together with its phenotype, SNT-8 proved to be a gammadelta T-cell line. This is the first report of the establishment of cell lines from primary lesions of nasal T/NK cell lymphomas, and the results demonstrated that there are at least 2 lineages, NK- and gammadelta T-cell, in this neoplasm. Moreover, it has been suggested that nasal T/NK cell lymphomas of these lineages may belong to the same clinicopathologic entity because both types of cases shared common clinical and histopathologic features.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157488     DOI: 10.1182/blood.v97.3.708

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma.

Authors:  Masayoshi Nagamine; Miki Takahara; Kan Kishibe; Toshihiro Nagato; Hideyuki Ishii; Nobuyuki Bandoh; Takeshi Ogino; Yasuaki Harabuchi
Journal:  Virus Genes       Date:  2006-08-18       Impact factor: 2.332

2.  An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection.

Authors:  Chongfeng Xu; Junhong Ai; Qingxun Zhang; Ting Li; Xiaorong Wu; Zhengde Xie; Ziyuan Duan
Journal:  J Vis Exp       Date:  2018-03-30       Impact factor: 1.355

3.  A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Authors:  Christopher P Fox; Tracey A Haigh; Graham S Taylor; Heather M Long; Steven P Lee; Claire Shannon-Lowe; Simon O'Connor; Catherine M Bollard; Javeed Iqbal; Wing C Chan; Alan B Rickinson; Andrew I Bell; Martin Rowe
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

4.  Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.

Authors:  Can Küçük; Bei Jiang; Xiaozhou Hu; Wenyan Zhang; John K C Chan; Wenming Xiao; Nathan Lack; Can Alkan; John C Williams; Kendra N Avery; Pınar Kavak; Anna Scuto; Emel Sen; Philippe Gaulard; Lou Staudt; Javeed Iqbal; Weiwei Zhang; Adam Cornish; Qiang Gong; Qunpei Yang; Hong Sun; Francesco d'Amore; Sirpa Leppä; Weiping Liu; Kai Fu; Laurence de Leval; Timothy McKeithan; Wing C Chan
Journal:  Nat Commun       Date:  2015-01-14       Impact factor: 14.919

5.  c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma.

Authors:  Takumi Kumai; Yoshinari Matsuda; Takayuki Ohkuri; Kensuke Oikawa; Kei Ishibashi; Naoko Aoki; Shoji Kimura; Yasuaki Harabuchi; Esteban Celis; Hiroya Kobayashi
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

6.  Restricted killer cell immunoglobulin-like receptor repertoire without T-cell receptor gamma rearrangement supports a true natural killer-cell lineage in a subset of sinonasal lymphomas.

Authors:  C W Lin; W H Lee; C L Chang; J Y Yang; S M Hsu
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

7.  Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type.

Authors:  Yenlin Huang; Aurélien de Reyniès; Laurence de Leval; Bouchra Ghazi; Nadine Martin-Garcia; Marion Travert; Jacques Bosq; Josette Brière; Barbara Petit; Emilie Thomas; Paul Coppo; Teresa Marafioti; Jean-François Emile; Marie-Hélène Delfau-Larue; Christian Schmitt; Philippe Gaulard
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

8.  Upregulation of LMP1 expression by histone deacetylase inhibitors in an EBV carrying NPC cell line.

Authors:  Jun Nishikawa; Lorand L Kis; Anquan Liu; Xiangning Zhang; Miki Takahara; Kentaro Bandobashi; Csaba Kiss; Noemi Nagy; Kiwamu Okita; George Klein; Eva Klein
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

9.  CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.

Authors:  Takumi Kumai; Toshihiro Nagato; Hiroya Kobayashi; Yuki Komabayashi; Seigo Ueda; Kan Kishibe; Takayuki Ohkuri; Miki Takahara; Esteban Celis; Yasuaki Harabuchi
Journal:  Cancer Immunol Immunother       Date:  2015-03-10       Impact factor: 6.968

Review 10.  Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease.

Authors:  Keisei Kawa
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.